Is Amdocs (DOX) Undervalued On Its AT&T Deal And Mixed Earnings Update?

Amdocs (DOX) just paired a mixed earnings update with an eight-year agreement to deepen its work with AT&T, putting fresh attention on how the telecom software provider balances guidance risk with long-term contracts.

Recent trading tells a mixed story. Amdocs shares are up 12.91% on a 90-day share price basis and 7.42% over 30 days, yet the year-to-date share price return is down 22.12% and the 1-year total shareholder return has declined 22.45%. This suggests that recent contract wins and the AT&T deal are only starting to rebuild momentum after a weaker stretch.

Compare Amdocs' contract-heavy AI story with a curated set of telecom and infrastructure plays by screening for 53 AI infrastructure stocks that could be positioned for additional upside.

Amdocs is now caught between a reset in expectations and a fresh stream of long contracts. After the recent rebound, the key question is whether the risk-reward still leans toward buyers or suggests patience as valuation gets unpacked next.

Most Popular Narrative: 24% Undervalued

Amdocs is trading at a last close of $62.43. The most followed valuation narrative on Simply Wall St points to a fair value of $82.03, which frames the recent rebound in a very different light.

Financially, the company is characterized by strong recurring revenue streams, highlighted by a high renewal rate for managed services, which account for approximately 65% of total revenue, and a substantial 12-month backlog of $4.28 billion. This stability allows the company to pursue a disciplined capital allocation strategy, featuring consistent dividend growth and significant share repurchases.

See why 41 investors see Amdocs as 24% undervalued.

Result: Fair Value of $82.03 (UNDERVALUED)

Still, the Amdocs thesis could be knocked off course if telecom clients slow spending on IT upgrades or if large contracts are repriced more aggressively.

Find out about the key risks to this Amdocs narrative.

Next Steps

The mix of optimism and concern around Amdocs is clear, so consider both sides carefully and decide where you land by checking the 4 key rewards and 1 important warning sign.

Looking for more investment ideas beyond Amdocs?

Do not stop with Amdocs. There are plenty of other opportunities worth lining up, and the right shortlist can save you a lot of time.

Use the Simply Wall St Screener to quickly surface focused sets of companies that match what you want from your next idea.

• Target quality at a discount by scanning a curated set of 35 high quality undervalued stocks that combine stronger fundamentals with more appealing pricing.
• Prioritise resilience and sleep easier at night by filtering for 30 resilient stocks with low risk scores that aim to limit downside while still leaving room for upside.
• Get ahead of the crowd by hunting through 19 high quality undiscovered gems that have solid business profiles yet attract far less attention.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com